Obesity is the top risk factor for severe COVID, study says - KatyMedSolutions

Obesity is the top risk factor for severe COVID, study says

A study from 56 countries shows that obesity is the top risk factor for severe COVID-19 cases among those under age 40.

As part of an agreement that includes the manufacture of COVID-19 vaccines, Translate Bio will receive milestone payments of $50 million from Sanofi for successfully producing mRNA shots.  

Indianapolis CDMO Exelead has delivered its first batch of Pfizer-BioNTech COVID-19 vaccines, the company said. 

The worldwide case count stood at more than 173.3 million on Monday morning, with more than 3.7 million reported deaths, according to Johns Hopkins University's COVID-19 dashboard.

Please read below for the latest updates. Daily COVID-19 tracker entries from Nov. 2 to April 28 can be found here. Entries from Aug. 11 to Oct. 30 are here. Entries from April 21 through Aug. 11 are here. Entries from Jan. 30 through April 20, 2020, are here.

UPDATED: Monday, June 7 at 3:40 p.m.

An analysis by Connecticut-based data and drug development specialist Phesi shows that obesity is the most significant risk factor predicting severe cases of COVID-19 in people under age 40. The study included more than 166,000 people from 56 countries.  

Translate Bio, a developer and manufacturer of mRNA therapeutics, has achieved a milestone related to its collaboration with Sanofi. Reaching the standard will allow Translate to collect $50 million from Sanofi for support of a phase 1 clinical trial for its influenza vaccine candidate. Translate entered the agreement with Sanofi to develop up to five mRNA vaccines, including one targeting COVID-19.

Indianapolis-based CDMO Exelead has delivered its first batch of Pfizer-BioNTech COVID-19 vaccine. The company expects to add 50 new jobs as part of the new collaboration. Exelead specializes in the manufacture of products that use liposome, lipid nanoparticle and pegylation technologies.

A Gallup poll shows that 76% of Americans are vaccinated or plan to be and that the rate has steadily risen since September of 2020, when only 50% of Americans said they would be inoculated. The poll, however, also reveals that roughly 1 in 5 in the U.S. will not seek vaccinations. Of those who said they would not seek them, 78% said they were unlikely to reconsider.

After promising lab results on hamsters, Swiss biotech Polypfor is considering its late-stage breast cancer candidate, balixafortide, as a COVID-19 treatment. A proof-of-concept study will be needed to initiate a phase 2 trial in COVID-19 patients. Story

Source: https://www.fiercepharma.com/pharma/covid-19-tracker-pfizer-vaccine-data-babies-could-come-by-september-spain-s-reig-jofre-to


Blog posts